Press Releases

<< Back
Printer Friendly Version View printer-friendly version
Download PDF Download PDF
Dr. Jason Yang spoke at 4th Annual Clinical Development and Trials Asia Congress & 5th Annual Pharma R&D Asia Congress Dr. Jason Yang, Senior Vice President of Clinical Development was invited to speak at 4th Annual Clinical Development and Trials Asia Congress & 5th Annual Pharma R&D Asia Congress, held in 27th & 28th January 2015, Shanghai, China. He presented on BeiGene’s oncology drug development strategy that focuses on novel targeted and immuno-oncology therapies and the combination of both to bring long lasting benefit to cancer patients. He also presented on the development strategy and experience to conduct early phase oncology clinical trials including study design and operations considerations. Finally, he gave an overview of BeiGene’s oncology pipeline of both small molecules and biologics and presented a high level update on the three anticancer agents currently under clinical study in Australia and New Zealand, including the 2nd generation BRAF inhibitor BGB-283, the PARP inhibitor BGB-290 and the BTK inhibitor BGB-3111.